The Imperial College London Diabetes Centre (ICLDC), a part of the M42 group, has demonstrated its leadership in diabetes research with nine studies published in high-impact peer-reviewed journals in 2024. These publications, appearing in respected outlets such as the International Journal of Obesity and Diabetes Obesity and Metabolism, offer valuable insights into novel treatments and diabetes management strategies.
Innovative research findings
Among the notable outcomes, ICLDC researchers have identified a potential new biomarker for predicting Type 2 diabetes and its associated complications. The centre’s studies have also evaluated the efficacy of emerging treatments, including Tirzepatide (Mounjaro) and Inclisiran (Leqvio), contributing to the advancement of diabetes therapeutics.
Furthermore, the research has established new approaches for digital based diabetes education, specifically tailored for individuals observing Ramadan fasting. This work addresses the unique challenges faced by diabetic patients during religious fasting periods, an area of particular relevance in the UAE context.
Recognition as an active research site
The Department of Health – Abu Dhabi (DoH) has officially designated ICLDC as an “Active Research Site”, acknowledging its high rate of scientific publications. This prestigious recognition, awarded to only three organisations, underscores ICLDC’s commitment to advancing medical knowledge in the field of diabetes.
Our ability to build successful relationships with both international and local partners, including the National Heart Centre Singapore and the contract research organisation, RAY, have been crucial in this success.
Dr Nader Lessan, Consultant Endocrinologist and Clinical Lead for Research at ICLDC, commented on the centre’s achievements: “This accomplishment reflects the commitment and enthusiasm of our team in the pursuit of advancing medical knowledge through research and education related to this disease. Our ability to build successful relationships with both international and local partners, including the National Heart Centre Singapore and the contract research organisation, RAY, have been crucial in this success.”
Leading role in international clinical trials
ICLDC has distinguished itself as the top recruiting site worldwide for the Asian Diabetes Outcomes Prevention Trial (ADOPT), a multinational, multi-centre research study. The centre’s research team, led by Dr Hani Sabour with support from Dr Lessan, Dr Farhana Bin Lootah, and Dr Omar Al Hariri, reached its pre-specified recruitment target in less than a year. Due to this outstanding performance, ICLDC was asked to double its target, highlighting its significant contribution to global diabetes research.
As ICLDC continues to expand its research portfolio, the centre remains dedicated to increasing awareness about diabetes causes, risks, and the importance of early detection. By combining cutting-edge research with public health initiatives, ICLDC aims to combat this complex disease and enhance community well-being.
The centre’s multifaceted approach to diabetes care, research, and education positions it as a key player in addressing the high prevalence of diabetes in the UAE and contributing to the broader global effort to improve diabetes management and outcomes.
